Ampligen Down, Probe Aims at Hemispherx Execs' Moves
By Randy Osborne
Thursday, December 20, 2012
Chronic fatigue syndrome patients willing to take Ampligen if it's approved and accept the risks, because it has worked for them in trials faced off against charges of inadequately done studies with less than satisfying overall efficacy signals, during a meeting of the FDA's Arthritis Advisory Committee.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.